• KSAN
  • Contact us
  • E-Submission

Korean J Adult Nurs : Korean Journal of Adult Nursing

OPEN ACCESS
mobile search button mobile menu button
Search
Advanced Search
ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS

Articles

Page Path

Original Article

Relationship between Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Patients with Hematologic Malignancies

Chi Eun Song1, Hye Young Kim2, Eun Sook Lee3
Korean Journal of Adult Nursing 2015;27(3):358-366.
Published online: June 30, 2015

1Department of Hematology, Chonnam National University Hwasun Hospital, Hwasun

2College of Nursing, Chonbuk National University, Jeonju

3Department of Nursing, Gyeongnam National University of Science and Technology, Jinju, Korea

Corresponding author: Kim, Hye Young College of Nursing, Chonbuk National University, 20 GunJi-ro, Deokjin-gu, Jeonju 561-712, Korea. Tel: +82-63-270-4618, Fax: +82-63-270-3127, E-mail: tcellkim@chonbuk.ac.kr
• Received: January 26, 2015   • Accepted: May 24, 2015

Copyright © 2015 Korean Society of Adult Nursing

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 22 Views
  • 1 Download
  • 2 Crossref
  • 2 Scopus
prev next

Full Article

Download PDF Download PDF
  • Purpose
    This study was aimed to identify the incidence and severity of chemotherapy-induced peripheral neuropathy (CIPN) among patients with hematologic malignancies and to examine the relationship between the quality of life (QOL) and CIPN.
  • Methods
    A total of 66 patients with CIPN-related symptoms participated in this study. Data were collected through self-reported questionnaires consisted of the European Organization for Research and Treatment of Cancer QLQ-C30 version 3.0 and the 16-item QLQ-CIPN20. Data were analyzed with SPSS/ WIN20 for descriptive statistics using the Mann-Whitney and Kruskal-Wallis tests, and Spearman's rho.
  • Results
    The mean lower and upper extremity scale scores were 31.95 and 23.16 respectively for the 16-item QLQ-CIPN20. The mean QLQ-C30 subcategory scores were 46.84 for global health status, 58.72 for functional scales, and 34.85 for symptom scales. The CIPN-related lower extremity scale symptoms correlated negatively with the QOL subscales. There was no correlation between CIPN-related upper extremity symptoms and health-related QOL.
  • Conclusion
    Patients with hematologic malignancies treated with neurotoxic chemotherapeutic agents had CIPN-related symptoms in the lower extremities mainly, and their QOL functional subscale scores were relatively lower than those of other cancer patients. Interventions need to be developed for patients with hematologic malignancies to alleviate CIPN and enhance their QOL.
  • Key Words: Quality of life; Chemotherapy; Peripheral neuropathies; Hematologic malignancy
Figure 1.
Percentage of patients who reported "quite a bit" or "very much"tingling, numbness, and/or shooting/burning pain on the 16-item QLQ-CIPN20 sensory scales.
kjan-27-358f1.jpg
Table 1.
Mean Rank Differences in CIPN and QOL, according to the General and Clinical Characteristics (N=66)
Characteristics Categories n (%) CIPN QOL
Lower extremity scales Upper extremity scales Global health status scales Functional scales Symptom scales
Mean rank p Mean rank p Mean rank p Mean rank p Mean rank p
Gender Male 43 (65.2) 34.94 .403 34.37 .612 34.53 .544 31.88 .349 34.44 .585
Female 23 (34.8) 30.80   31.87   31.57   36.52   31.74  
Age (year) ≤49 15 (22.7) 19.67 .004 30.07 .759 44.33 .038 47.20 .014 21.87 .060
50–59 20 (30.3) 35.55   36.78   34.98   31.60   38.60  
60–69 15 (22.7) 33.03   34.07   28.27   30.10   35.30  
≥70 16 (24.2) 44.34   32.09   26.41   26.22   36.34  
Education ≤Middle school 24 (36.3) 41.69 .009 30.19 .287 27.71 .060 25.92 .015 38.81 .089
≥High school 42 (63.7) 28.82   35.39   36.81   37.83   30.46  
Employment Yes 22 (33.3) 32.16 .688 31.41 .529 32.07 .664 33.64 .967 30.64 .391
No 44 (66.7) 34.17   34.55   34.22   33.43   34.93  
ECOG PS ≤1 55 (83.3) 31.05 .020 33.05 .665 36.25 .008 35.99 .018 31.92 .134
≥2 11 (16.7) 45.73   35.77   19.73   21.05   41.41  
Diagnosis ALL 7 (10.6) 24.86 ＜.001 38.21 .778 25.86 .309 30.50 .097 35.79 .303
NHL 28 (42.4) 24.21   33.36   37.09   39.41   29.27  
MM 31 (47.0) 43.84   32.56   31.98   28.84   36.81  
Duration of diagnosis (months) ≤4 18 (27.3) 24.36 .025 33.58 .837 29.11 .063 33.86 .027 35.86 .093
5–12 18 (27.3) 30.33   30.83   43.75   43.53   23.83  
13–24 9 (13.6) 37.94   32.11   29.06   32.83   37.39  
≥25 21 (31.8) 42.14   36.31   30.38   24.88   38.10  
Current chemotherapy Yes 46 (69.7) 33.72 .889 34.29 .609 32.71 .606 31.17 .135 37.80 .006
No 20 (30.3) 33.00   31.68   35.33   38.85   23.60  
Duration of CIPN (month) ≤4 26 (39.4) 21.02 ＜.001 33.87 .833 32.15 .173 36.42 .008 31.83 .071
5–12 17 (25.8) 36.72   29.25   41.16   41.63   25.34  
13–24 6 (9.0) 38.00   35.00   32.42   31.17   31.67  
≥25 17 (25.8) 46.06   34.50   26.82   20.29   42.47  
Exposure to neurotoxic agents Single 45 (68.2) 26.83 ＜.001 32.83 .678 35.16 .298 37.42 .015 30.02 .031
Multiple 21 (31.8) 47.79   34.93   29.95   25.10   40.95  
                       

CIPN=chemotherapy-induced peripheral neuropathy; QOL=quality of life; ECOG PS=Eastern Cooperative Oncology Group performance status; ALL=Acute lymphocytic leukemia; NHL=non-Hodgkin lymphoma; MM=multiple myeloma.

Table 2.
Scores from the 16-item QLQ-CIPN20 Subscales and EORTC QLQ-C30 Subscales (N=66)
Variables   M±SD
16-item QLQ-CIPN20 Lower extremity scales 31.95±23.30
Upper extremity scales 23.16±19.01
EORTC QLQ-C30 　 Global health status scales 46.84±21.62
Functional scales 58.72±20.61
Physical scales 56.24±21.71
Role scales 51.01±36.97
Emotional scales 71.46±25.61
Cognitive scales 62.12±28.58
Social scales 41.16±36.19
Symptom scales 34.85±16.79
Fatigue 55.22±27.90
Nausea & vomiting 11.11±16.10
Pain 30.56±30.74
Dyspnea 41.41±35.60
Insomnia 37.88±38.73
Appetite loss 37.88±36.46
Constipation 22.22±36.20
Diarrhea 12.12±21.59
Financial problem 52.53±40.95

16-item QLQ-CIPN20=16-item quality of life questionnaire-chemotherapy-induced peripheral neuropathy; EORTC QLQ-C30= European Organization for the Research and Treatment of Cancer quality of life questionnaire core 30 items.

Table 3.
Correlation between Health-related QOL and Peripheral Neuropathy Status (N=66)
Subscales in EORTC QLQ-C30 Subscales in 16-item QLQ-CIPN
Lower extremity Upper extremity
rho (p) rho (p)
Global health status -.243 (.050) -.075 (.550)
Functional -.469 (.002) -.236 (.057)
Symptom .463 (.002) .126 (.314)

QOL=quality of life; 16-item; QLQ-CIPN20=16-item quality of life questionnaire-chemotherapy-induced peripheral neuropathy; EORTC QLQ-C30=European Organization for the Research and Treatment of Cancer quality of life questionnaire core 30 items.

  • 1.Wickham R. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice. Clinical Journal of Oncology Nursing. 2007;11(3):361-76.
  • 2.Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. European Journal of Cancer. 2005;41(8):1135-39.
  • 3.Tofthagen C. Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clinical Journal of Oncology Nursing. 2010;14(3):E22-8. http://dx.doi.org/10.1188/10.CJON.E22-E28.
  • 4.Ocean AJ, Vahdat LT. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Supportive Care in Cancer. 2004;12(9):619-25.
  • 5.Kautio AL, Haanpää M, Kautiainen H, Kalso E, Saarto T. Burden of chemotherapy-induced neuropathy-a cross-sectional study. Supportive Care in Cancer. 2011;19(12):1991-6. http://dx.doi.org/10.1007/s00520-010-1043-2.
  • 6.Delforge M, Blade J, Dimopoulos M, Facon T, Kropff M, Ludwig H, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. The Lancet. 2010;11(11):1086-95. http://dx.doi.org/10.1016/S1470-2045(10)70068-1.
  • 7.Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrel-lo I. Characteristics of bortezomib- and thalidomideinduced peripheral neuropathy. Journal of the Peripheral Nervous System. 2008;13(4):275-82.
  • 8.Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Journal of Clinical Oncology. 2006;24(19):3113-20.
  • 9.Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer. 2007;110(5):1042-9.
  • 10.Berkowitz A, Walker S. Bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Clinical Journal of Oncology Nursing. 2012;16(1):86-9. http://dx.doi.org/10.1188/12.CJON.86-89.
  • 11.Kim JH, Choi KS, Kim TW, Hong YS. Quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy. Journal of Korean Oncology Nursing. 2011;11(3):254-62. http://dx.doi.org/10.5388/jkon.2011.11.3.254.
  • 12.Kiser DW, Greer TB, Wilmoth MC, Dmochowski J, Naumann RW. Peripheral neuropathy in patients with gynecologic cancer receiving chemotherapy: patient reports and provider assessment. Oncology Nursing Forum. 2010;37(6):758-64. http://dx.doi.org/10.1188/10.ONF.758-764.
  • 13.Tofthagen C, McAllister RD, McMillan SC. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clinical Journal of Oncology Nursing. 2011;15(2):182-8. http://dx.doi.org/10.1188/11.CJON.182-188.
  • 14.Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clinical Journal of Oncology Nursing. 2007;11(6):901-13.
  • 15.Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Supportive Care in Cancer. 2011;19(6):833-41. http://dx.doi.org/10.1007/s00520-010-0911-0.
  • 16.Clark PG, Cortese-Jimenez G, Cohen E. Effects of reiki, yoga, or meditation on the physical and psychological symptoms of chemotherapy-induced peripheral neuropathy: arandomized pilot study. Journal of Evidence-Based Complementary & Alternative Medicine. 2012;17(3):161-71. http://dx.doi.org/10.1177/2156587212450175.
  • 17.Donald GK, Tobin I, Stringer J. Evaluation of acupuncture in the management of chemotherapy-induced peripheral neuropathy. Acupuncture in Medicine. 2011;29(3):230-3. http://dx.doi.org/10.1136/acupmed.2011.010025.
  • 18.Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. Journal of the American Medical Association. 2013;309(13):1359-67. http://dx.doi.org/10.1001/jama.2013.2813.
  • 19.Yoon J, Jeon JH, Lee YW, Cho CK, Kwon KR, Shin JE, et al. Sweet bee venom pharmacopuncture for chemotherapy induced peripheral neuropathy. Journal of Acupuncture & Meridian Studies. 2012;5(4):156-65. http://dx.doi.org/10.1016/j.jams.2012.05.003.
  • 20.Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Fri-geni B, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Annals of Oncology. 2013;24(2):454-62. http://dx.doi.org/10.1093/annonc/mds329.
  • 21.Kim HY, Kang JH, Song CE, Youn HJ. Chemotherapy-induced peripheral neuropathy and quality of life in breast cancer patients. Asian Oncology Nursing. 2013;13(4):222-30. http://dx.doi.org/10.5388/aon.2013.13.4.222.
  • 22.Kim HY, Kang JH, Youn HJ, So HS, Song CE, Chae SY, et al. Reliability and validity of the Korean version of the European Organization for Research and Treatment of Cancer Quality of Life questionnaire to assess chemotherapy-induced peripheral neuropathy. Journal of Korean Academy of Nursing. 2014;44(6):735-42. http://dx.doi.org/10.4040/jkan.2014.44.6.735.
  • 23.Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behavior Research Methods. 2009;41(4):1149-60.
  • 24.Lavoie Smith EM, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL. Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Quality of Life Research. 2013;22(10):2787-99. http://dx.doi.org/10.1007/s11136-013-0379-8.
  • 25.Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, et alThe EORTC QLQ-C30 Scoring Manual. 3rd ed.. Brussels: European Organization for Research and Treatment of Cancer; 2001.
  • 26.Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, et al. Validation of the Korean version of the EORTC QLQ-C30. Quality of Life Research. 2004;13(4):863-8.
  • 27.Wolf SL, Barton DL, Qin R, Wos EJ, Sloan JA, Liu H, et al. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapyinduced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN instrument, N06CA. Supportive Care in Cancer. 2012;20(3):625-32. http://dx.doi.org/10.1007/s00520-011-1141-9.
  • 28.Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatmentstrategies. European Journal of Cancer. 2008;44:1507-15. http://dx.doi.org/10.1016/j.ejca.2008.04.018.
  • 29.Kwak MK, Kim EJ, Lee ER, Kwon IG, Hwang MS. Characteristics and quality of life in patients with chemotherapy-induced peripheral neuropathy. Journal of Korean Oncology Nursing. 2010;10(2):231-9. http://dx.doi.org/10.5388/jkon.2010.10.2.231.

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Taxane-induced peripheral neuropathy and quality of life in breast cancer patients
      Ebrahim Salehifar, Ghasem Janbabaei, Abbas Alipour, Nasim Tabrizi, Razieh Avan
      Journal of Oncology Pharmacy Practice.2020; 26(6): 1421.     CrossRef
    • Oxaliplatin-Induced Peripheral Neuropathy and Quality of Life in Patients with Digestive System Cancer
      Hye Young Kim
      Korean Journal of Adult Nursing.2016; 28(3): 343.     CrossRef

    Download Citation

    Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

    Format:

    Include:

    Relationship between Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Patients with Hematologic Malignancies
    Korean J Adult Nurs. 2015;27(3):358-366.   Published online June 30, 2015
    DOI: https://doi.org/10.7475/kjan.2015.27.3.358
    Download Citation
    Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
    Format:
    • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
    • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
    Include:
    • Citation for the content below
    Relationship between Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Patients with Hematologic Malignancies
    Korean J Adult Nurs. 2015;27(3):358-366.   Published online June 30, 2015
    DOI: https://doi.org/10.7475/kjan.2015.27.3.358
    Close

    Figure

    • 0
    Relationship between Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Patients with Hematologic Malignancies
    Image
    Figure 1. Percentage of patients who reported "quite a bit" or "very much"tingling, numbness, and/or shooting/burning pain on the 16-item QLQ-CIPN20 sensory scales.

    Figure 1.

    Relationship between Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Patients with Hematologic Malignancies

    Mean Rank Differences in CIPN and QOL, according to the General and Clinical Characteristics (N=66)

    Characteristics Categories n (%) CIPN QOL
    Lower extremity scales Upper extremity scales Global health status scales Functional scales Symptom scales
    Mean rank p Mean rank p Mean rank p Mean rank p Mean rank p
    Gender Male 43 (65.2) 34.94 .403 34.37 .612 34.53 .544 31.88 .349 34.44 .585
    Female 23 (34.8) 30.80   31.87   31.57   36.52   31.74  
    Age (year) ≤49 15 (22.7) 19.67 .004 30.07 .759 44.33 .038 47.20 .014 21.87 .060
    50–59 20 (30.3) 35.55   36.78   34.98   31.60   38.60  
    60–69 15 (22.7) 33.03   34.07   28.27   30.10   35.30  
    ≥70 16 (24.2) 44.34   32.09   26.41   26.22   36.34  
    Education ≤Middle school 24 (36.3) 41.69 .009 30.19 .287 27.71 .060 25.92 .015 38.81 .089
    ≥High school 42 (63.7) 28.82   35.39   36.81   37.83   30.46  
    Employment Yes 22 (33.3) 32.16 .688 31.41 .529 32.07 .664 33.64 .967 30.64 .391
    No 44 (66.7) 34.17   34.55   34.22   33.43   34.93  
    ECOG PS ≤1 55 (83.3) 31.05 .020 33.05 .665 36.25 .008 35.99 .018 31.92 .134
    ≥2 11 (16.7) 45.73   35.77   19.73   21.05   41.41  
    Diagnosis ALL 7 (10.6) 24.86 ＜.001 38.21 .778 25.86 .309 30.50 .097 35.79 .303
    NHL 28 (42.4) 24.21   33.36   37.09   39.41   29.27  
    MM 31 (47.0) 43.84   32.56   31.98   28.84   36.81  
    Duration of diagnosis (months) ≤4 18 (27.3) 24.36 .025 33.58 .837 29.11 .063 33.86 .027 35.86 .093
    5–12 18 (27.3) 30.33   30.83   43.75   43.53   23.83  
    13–24 9 (13.6) 37.94   32.11   29.06   32.83   37.39  
    ≥25 21 (31.8) 42.14   36.31   30.38   24.88   38.10  
    Current chemotherapy Yes 46 (69.7) 33.72 .889 34.29 .609 32.71 .606 31.17 .135 37.80 .006
    No 20 (30.3) 33.00   31.68   35.33   38.85   23.60  
    Duration of CIPN (month) ≤4 26 (39.4) 21.02 ＜.001 33.87 .833 32.15 .173 36.42 .008 31.83 .071
    5–12 17 (25.8) 36.72   29.25   41.16   41.63   25.34  
    13–24 6 (9.0) 38.00   35.00   32.42   31.17   31.67  
    ≥25 17 (25.8) 46.06   34.50   26.82   20.29   42.47  
    Exposure to neurotoxic agents Single 45 (68.2) 26.83 ＜.001 32.83 .678 35.16 .298 37.42 .015 30.02 .031
    Multiple 21 (31.8) 47.79   34.93   29.95   25.10   40.95  
                           

    CIPN=chemotherapy-induced peripheral neuropathy; QOL=quality of life; ECOG PS=Eastern Cooperative Oncology Group performance status; ALL=Acute lymphocytic leukemia; NHL=non-Hodgkin lymphoma; MM=multiple myeloma.

    Scores from the 16-item QLQ-CIPN20 Subscales and EORTC QLQ-C30 Subscales (N=66)

    Variables   M±SD
    16-item QLQ-CIPN20 Lower extremity scales 31.95±23.30
    Upper extremity scales 23.16±19.01
    EORTC QLQ-C30 　 Global health status scales 46.84±21.62
    Functional scales 58.72±20.61
    Physical scales 56.24±21.71
    Role scales 51.01±36.97
    Emotional scales 71.46±25.61
    Cognitive scales 62.12±28.58
    Social scales 41.16±36.19
    Symptom scales 34.85±16.79
    Fatigue 55.22±27.90
    Nausea & vomiting 11.11±16.10
    Pain 30.56±30.74
    Dyspnea 41.41±35.60
    Insomnia 37.88±38.73
    Appetite loss 37.88±36.46
    Constipation 22.22±36.20
    Diarrhea 12.12±21.59
    Financial problem 52.53±40.95

    16-item QLQ-CIPN20=16-item quality of life questionnaire-chemotherapy-induced peripheral neuropathy; EORTC QLQ-C30= European Organization for the Research and Treatment of Cancer quality of life questionnaire core 30 items.

    Correlation between Health-related QOL and Peripheral Neuropathy Status (N=66)

    Subscales in EORTC QLQ-C30 Subscales in 16-item QLQ-CIPN
    Lower extremity Upper extremity
    rho (p) rho (p)
    Global health status -.243 (.050) -.075 (.550)
    Functional -.469 (.002) -.236 (.057)
    Symptom .463 (.002) .126 (.314)

    QOL=quality of life; 16-item; QLQ-CIPN20=16-item quality of life questionnaire-chemotherapy-induced peripheral neuropathy; EORTC QLQ-C30=European Organization for the Research and Treatment of Cancer quality of life questionnaire core 30 items.
    Table 1. Mean Rank Differences in CIPN and QOL, according to the General and Clinical Characteristics (N=66)

    CIPN=chemotherapy-induced peripheral neuropathy; QOL=quality of life; ECOG PS=Eastern Cooperative Oncology Group performance status; ALL=Acute lymphocytic leukemia; NHL=non-Hodgkin lymphoma; MM=multiple myeloma.

    Table 2. Scores from the 16-item QLQ-CIPN20 Subscales and EORTC QLQ-C30 Subscales (N=66)

    16-item QLQ-CIPN20=16-item quality of life questionnaire-chemotherapy-induced peripheral neuropathy; EORTC QLQ-C30= European Organization for the Research and Treatment of Cancer quality of life questionnaire core 30 items.

    Table 3. Correlation between Health-related QOL and Peripheral Neuropathy Status (N=66)

    QOL=quality of life; 16-item; QLQ-CIPN20=16-item quality of life questionnaire-chemotherapy-induced peripheral neuropathy; EORTC QLQ-C30=European Organization for the Research and Treatment of Cancer quality of life questionnaire core 30 items.

    Table 1.

    Table 2.

    Table 3.

    Korean J Adult Nurs : Korean Journal of Adult Nursing

    ABOUT

    BROWSE ARTICLES 

    EDITORIAL POLICY

    FOR CONTRIBUTORS  

    © Korean Society of Adult Nursing.
    TOP